SCAI Therapeutics
PrivateLast Round
Series C
Jul 10, 2026
Est. Valuation
$74.58M
Total Funding Raised
$42.83M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SCAI Therapeutics operates in Healthcare & Life Sciences and is based in Daejeon. Its latest recorded funding round was a Series C round in July 2026.
SCAI Therapeutics is a biotechnology company that develops novel drugs and cosmetic ingredients using its proprietary MOASIS drug delivery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Fashion & Beauty
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SCAI Therapeutics Comparables
Compare SCAI Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SHIFTBIO | 81% | |
| Zerion Pharma | 80% | |
| Pnaseer Inc. | 80% |
For institutional investors. Book with your work email.
SCAI Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 10, 2026 | ||||
| Series B | Jul 14, 2021 | ||||
| Series A | Nov 1, 2019 |
For institutional investors. Book with your work email.
SCAI Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BonAngels Venture Partners | Series C |
| Timefolio Asset Management | Series B |
| Stonebridge Ventures | Series A, Series B |
| Heungkuk Securities | Series B |
| Lifecore Partners | Series B |
| HB Investment | Series B |
| IMM Investment | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 10, 2026
Raised $9M with BonAngels Venture Partners and Solidus Investment.
- Jun 16, 2026
Monthly visitors increased 336% MoM, reaching 4K.
For institutional investors. Book with your work email.
SCAI Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SCAI Therapeutics's valuation, stock price, and market status.
Is SCAI Therapeutics a public or private company?
SCAI Therapeutics is a private company.
What is the current stock price of SCAI Therapeutics?
SCAI Therapeutics is a private company, so its shares have no public market price. Caplight tracks SCAI Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SCAI Therapeutics worth (valuation)?
SCAI Therapeutics's valuation is estimated at $74.6M based on funding round data.
Can I buy SCAI Therapeutics stock?
SCAI Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SCAI Therapeutics's last funding round?
SCAI Therapeutics's most recent funding round was Series C on July 10, 2026.
Who are the main investors in SCAI Therapeutics?
Key investors in SCAI Therapeutics include BonAngels Venture Partners, Timefolio Asset Management, Stonebridge Ventures, Heungkuk Securities, Lifecore Partners.
Will SCAI Therapeutics IPO soon?
No public IPO plans have been announced for SCAI Therapeutics.
How can I track SCAI Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SCAI Therapeutics's shares on secondary markets.